Prostate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]
Recent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]
Acoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]
Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]
Relugolix (Orgovyx), the first oral androgen deprivation therapy approved for advanced prostate cancer, continues to show consistent performance in real-world settings. New data from the OPTYX study, a prospective observational analysis, provide further evidence on testosterone suppression, recovery, and PSA control in routine clinical practice. The study included 999 patients, predominantly with nonmetastatic disease and […]
Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]
ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]
Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]
Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is approaching, but research never stops! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 3 Trial: The PROTEUS Trial […]